Extended RAS Analysis and Correlation with Overall Survival in Advanced Pancreatic Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2017 Apr 28

PMID 28449008

Citations 20

Authors

Michael Haas

Steffen Ormanns

Sibylle Baechmann

Anna Remold

Stephan Kruger

Christoph B Westphalen

Jens T Siveke

Patrick Wenzel

Anna Melissa Schlitter

Irene Esposito

Detlef Quietzsch

Michael R Clemens

Erika Kettner

Ruediger P Laubender

Andreas Jung

Thomas Kirchner

Stefan Boeck

Volker Heinemann

Affiliations

Soon will be listed here.

Abstract

Background: Mutations in the KRAS gene can be detected in about 70-90% of pancreatic cancer (PC) cases. Whether these mutations have a prognostic or predictive value remains elusive. Furthermore, the clinical relevance of the extended RAS (KRAS+NRAS) mutational status is unclear in PC.

Methods: We prospectively defined a PC patient population who received erlotinib-free chemotherapy regimens. A statistically significant difference between KRAS wild-type and KRAS mutated tumours in at least 160 patients in this population would support the assumption of a rather prognostic role of KRAS.

Results: One hundred and seventy-eight tumour samples were collected from prospective clinical studies and successfully analysed for the extended RAS status: 37 tumours were KRAS wild-type (21%), whereas 141 (79%) carried a KRAS mutation; 132 of these mutations were found in KRAS exon 2 (74%), whereas only 9 mutations (5%) were detected in KRAS exon 3. Within KRAS exon 4 and NRAS exons 2-4, no mutations were apparent. There was no significant difference in overall survival for KRAS wild-type vs mutant patients (9.9 vs 8.3 months, P=0.70).

Conclusions: Together with the results of the AIO-PK-0104-trial, the present analysis supports the notion that KRAS mutation status is rather predictive than prognostic in advanced PC.

Citing Articles

Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospective Cohort Study.

Chun J, Lee D, Han N, Heo S, Kim H, Lee M Cancers (Basel). 2025; 17(5).

PMID: 40075743 PMC: 11899085. DOI: 10.3390/cancers17050896.

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.

Yang X, Wu H J Hematol Oncol. 2024; 17(1):108.

PMID: 39522047 PMC: 11550559. DOI: 10.1186/s13045-024-01631-9.

Prognostic Role of Specific Mutations Detected in Aspiration and Liquid Biopsies from Patients with Pancreatic Cancer.

Halkova T, Bunganic B, Traboulsi E, Minarik M, Zavoral M, Benesova L Genes (Basel). 2024; 15(10).

PMID: 39457426 PMC: 11507146. DOI: 10.3390/genes15101302.

Unveiling the role of in Chinese colorectal cancer patients: a positive influence on tumor mutational burden.

Wan X, Zhang X, Xu M, Zheng Z, Zhou Y, Zhong Z Transl Cancer Res. 2024; 13(9):4752-4762.

PMID: 39430843 PMC: 11483435. DOI: 10.21037/tcr-24-600.

TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer.

Guenther M, Surendran S, Haas M, Heinemann V, von Bergwelt-Baildon M, Engel J Br J Cancer. 2023; 129(1):175-182.

PMID: 37142730 PMC: 10307892. DOI: 10.1038/s41416-023-02295-x.

References

Kruger S, Haas M, Ormanns S, Bachmann S, Siveke J, Kirchner T . Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts. World J Gastroenterol. 2014; 20(31):10769-77. PMC: 4138457. DOI: 10.3748/wjg.v20.i31.10769. View

Shin S, Kim S, Hong S, Kim Y, Song K, Park K . Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas. 2013; 42(2):216-22. DOI: 10.1097/MPA.0b013e31825b6ab0. View

Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C . Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005; 7(3):413-21. PMC: 1867544. DOI: 10.1016/S1525-1578(10)60571-5. View

Schlitter A, Jang K, Kloppel G, Saka B, Hong S, Choi H . Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Mod Pathol. 2015; 28(9):1249-64. DOI: 10.1038/modpathol.2015.61. View

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

Kwon M, Jeon J, Park H, Nam E, Cho S, Shin H . Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value. Pancreas. 2014; 44(3):484-92. DOI: 10.1097/MPA.0000000000000280. View

Tao L, Zhang L, Xiu D, Yuan C, Ma Z, Jiang B . Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis. World J Surg Oncol. 2016; 14:146. PMC: 4868030. DOI: 10.1186/s12957-016-0888-3. View

Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A . Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol. 2007; 19(2):340-7. DOI: 10.1093/annonc/mdm467. View

Amado R, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10):1626-34. DOI: 10.1200/JCO.2007.14.7116. View

10.

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

11.

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

12.

Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Marten A, Winkelmann C . Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.... Gut. 2012; 62(5):751-9. PMC: 6309814. DOI: 10.1136/gutjnl-2012-302759. View

13.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A . Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24(24):3946-52. DOI: 10.1200/JCO.2005.05.1490. View

14.

da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S . Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer. 2010; 116(24):5599-607. DOI: 10.1002/cncr.25393. View

15.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

16.

Ogura T, Yamao K, Hara K, Mizuno N, Hijioka S, Imaoka H . Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol. 2012; 48(5):640-6. DOI: 10.1007/s00535-012-0664-2. View

17.

Tsiatis A, Norris-Kirby A, Rich R, Hafez M, Gocke C, Eshleman J . Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010; 12(4):425-32. PMC: 2893626. DOI: 10.2353/jmoldx.2010.090188. View

18.

Wang J, Wu C, Yeh Y, Shyr Y, Wu Y, Kuo C . Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget. 2015; 6(20):18162-73. PMC: 4627242. DOI: 10.18632/oncotarget.4216. View

19.

Sinn B, Striefler J, Rudl M, Lehmann A, Bahra M, Denkert C . KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Pancreas. 2014; 43(4):578-83. DOI: 10.1097/MPA.0000000000000077. View

20.

Douillard J, Oliner K, Siena S, Tabernero J, Burkes R, Barugel M . Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369(11):1023-34. DOI: 10.1056/NEJMoa1305275. View